Glucosamine: One of the Best-Vetted Anti-Aging Supplements — Strongly Associated With an Extension in HUMAN Lifespan

by Nils Osmar

The information in this article is not intended as, and should not be taken as, medical advice. Interventions like exercising, dietary changes, and taking medications and supplements can have both benefits and side effects, Please consult with a medical professional about any medical concerns.  See full Medical Disclaimer

Glucosamine is one of the world’s most popular dietary supplements. An estimated 19–22% of adults over 45 in the US, UK, and Australia take it regularly, almost always for joint pain or osteoarthritis. It’s cheap, widely available without a prescription, and has an excellent safety profile built up over decades of use.

But over the past several years, a series of large-scale studies have revealed something surprising: people who take glucosamine appear to live significantly longer than those who don’t — and the effect sizes rival those of regular exercise. Many supplements and medications are associated with life extension in flies, mice and rats; glucosamine is associated with striking improvements in human mortality. The mortality reductions show up across cardiovascular disease, cancer, respiratory illness, and digestive disease.

The mechanisms behind these effects, now supported by both animal studies and molecular research, place glucosamine squarely in the category of caloric restriction mimetics — compounds that trigger the same cellular housekeeping pathways activated by fasting and caloric restriction.

For a supplement that costs roughly $10–15 per month, the emerging picture is remarkable.

The Mortality Evidence

The strongest evidence comes from several large prospective cohort studies, each drawing on tens or hundreds of thousands of participants followed over many years.

The UK Biobank Study (2020)

The largest and most comprehensive study was published in the Annals of the Rheumatic Diseases (Li et al., 2020). It followed 495,077 participants from the UK Biobank over a median of 8.9 years. Among them, 19.1% reported regular glucosamine use at baseline.

After adjusting for a wide range of confounders — age, sex, smoking, alcohol, physical activity, BMI, diet, existing diseases, and use of other supplements and medications — the researchers found that regular glucosamine use was associated with:

• 15% lower all-cause mortality (HR 0.85)
• 18% lower cardiovascular mortality (HR 0.82)
• 6% lower cancer mortality (HR 0.94)
• 27% lower respiratory disease mortality (HR 0.73)
• 26% lower digestive disease mortality (HR 0.74)

These associations held up in sensitivity analyses that excluded chondroitin users, suggesting the effects were attributable to glucosamine itself rather than to the chondroitin that often accompanies it in combination supplements.

The US NHANES Study (2020)

A second study, published the same year in the Journal of the American Board of Family Medicine (King & Xiang, 2020), analyzed data from 16,686 participants in the US National Health and Nutrition Examination Survey (NHANES), followed for a median of 107 months.

The findings were even more striking: daily use of glucosamine/chondroitin for a year or longer was associated with a 39% reduction in all-cause mortality and a 65% reduction in cardiovascular deaths. These are very large effect sizes — the lead researcher, Dana King of West Virginia University, noted that the mortality reduction was comparable to that seen with regular physical exercise.

The VITAL Cohort (2012)

An earlier study from Washington state (Pocobelli et al., 2010/2012) followed participants in the VITamins And Lifestyle (VITAL) cohort and found that current glucosamine use was associated with a 13% reduction in cancer mortality and a 33% reduction in deaths from other causes, including a notably large risk reduction for respiratory disease deaths.

Mendelian Randomization: Getting Closer to Causation

Observational studies, no matter how carefully adjusted, are always vulnerable to the healthy user bias — the possibility that people who take glucosamine are simply healthier, more health-conscious, or wealthier than those who don’t. This is a legitimate concern.

This is where a 2022 Mendelian randomization (MR) study by Yoon and Narayan becomes important. MR studies use naturally occurring genetic variants as “instruments” to test causal relationships. Because genetic variants are randomly assigned at conception, they aren’t affected by the lifestyle confounders that plague observational research.

Using genetic data from over 460,000 individuals in the UK Biobank, the researchers found that genetically predicted higher glucosamine levels were associated with significantly greater combined parental longevity. The effect was particularly strong for maternal lifespan, though not statistically significant for paternal lifespan — an intriguing sex-specific finding that awaits further investigation.

This MR evidence doesn’t definitively prove causation, but it substantially strengthens the case that the mortality association isn’t simply an artifact of healthier people choosing to take glucosamine.

Why It Works: Glucosamine as a Caloric Restriction Mimetic

For decades, researchers have known that caloric restriction — reducing calorie intake by 20–40% without malnutrition — extends lifespan in organisms ranging from yeast to primates. The challenge has always been that sustained caloric restriction is extremely difficult for humans to maintain. This has fueled intense interest in caloric restriction mimetics (CRMs): compounds that activate the same protective cellular pathways without requiring you to eat less.

Glucosamine, it turns out, is one of the most promising CRMs identified to date. And unlike some others (such as 2-deoxyglucose, which proved too toxic for practical use), glucosamine has been safely consumed by millions of people for decades.

The Core Mechanism: Glycolysis Inhibition → AMPK Activation

The mechanistic story was laid out in a landmark 2014 paper published in Nature Communications by Weimer et al. The researchers demonstrated that D-glucosamine acts as an inhibitor of glycolysis — it interferes with the cell’s primary glucose-burning pathway. This is a form of metabolic deception: the cell perceives an energy deficit, even when calories are plentiful.

This perceived energy shortfall activates AMPK (AMP-activated protein kinase), the cell’s master energy sensor and a central regulator of longevity pathways across species. AMPK activation, in turn, triggers a cascade of protective responses:

1. Increased mitochondrial biogenesis — the cell produces more mitochondria and improves their efficiency
2. Activation of autophagy — the cell’s recycling and repair system, which clears out damaged proteins and dysfunctional organelles
3. Inhibition of mTOR — the growth-signaling pathway whose chronic overactivation is associated with aging and age-related disease
4. Upregulation of NRF2/SKN-1 — transcription factors that activate antioxidant and stress-resistance genes

The Weimer study showed that this mechanism extends lifespan in C. elegans (nematode worms) and, crucially, also extends lifespan in aging mice — a much more meaningful result from a translational standpoint.

Mitohormesis: A Controlled Stress Response

The mechanism involves a process called mitohormesis. When glucosamine impairs glycolysis and shifts energy metabolism, it triggers a transient increase in mitochondrial reactive oxygen species (ROS). This sounds harmful, but at moderate levels, ROS act as signaling molecules that activate protective stress responses — upregulating antioxidant enzymes, improving oxidative stress resistance, and enhancing cellular repair.

This is the same principle behind the health benefits of exercise: a temporary metabolic stress that makes the organism more resilient. In fact, the Weimer study found that blocking this ROS signaling abolished the lifespan extension, confirming that it’s the hormetic stress response — not a simple antioxidant effect — that drives the benefit.

A 2021 study by Kumar, Saraswat, and Rizvi (Rejuvenation Research) confirmed this pattern in a rat aging model, finding that glucosamine activated mitohormesis and improved multiple aging biomarkers in both young and accelerated-aging rats.

Autophagy: Cellular Housekeeping

Multiple studies have confirmed that glucosamine is a potent inducer of autophagy. A 2021 study in the Proceedings of the Japan Academy demonstrated that glucosamine extended C. elegans lifespan by approximately 30% at optimal doses, and that this extension was entirely dependent on autophagy-related genes — when the researchers knocked out autophagy pathways, the lifespan benefit disappeared.

A 2018 study in the International Journal of Molecular Sciences provided detailed molecular evidence that glucosamine induces autophagy specifically through the AMPK-mTOR pathway in human retinal pigment epithelial cells, with a dose-dependent increase in AMPK phosphorylation and a corresponding decrease in mTOR phosphorylation.

NF-κB Inhibition: Dampening Chronic Inflammation

Glucosamine also inhibits NF-κB, a transcription factor that lies upstream of many inflammatory processes and is chronically overactivated in aging (a phenomenon sometimes called “inflammaging”). Laboratory studies have shown that glucosamine and chondroitin inhibit NF-κB nuclear translocation and suppress downstream inflammatory mediators including IL-1β, IL-6, TNF-α, PGE2, and COX-2.

This anti-inflammatory mechanism is likely a major contributor to the cardiovascular and cancer mortality reductions observed in the epidemiological studies, since chronic low-grade inflammation is a driver of both atherosclerosis and tumor development.

The Diseases of Aging: Where the Associations Are Strongest

Cardiovascular Disease

The cardiovascular signal is one of the most robust. A 2019 study in the BMJ (Ma et al.) specifically examined the association between habitual glucosamine use and cardiovascular outcomes in the UK Biobank and found significant protective associations. The NHANES study found a striking 65% reduction in cardiovascular mortality among regular users, and even the more conservative UK Biobank estimate showed an 18% reduction.

The mechanisms align well: AMPK activation improves endothelial function, glucosamine has been shown to improve vascular endothelial function by modulating intracellular redox state, and NF-κB inhibition reduces the inflammatory processes that drive atherosclerosis.

A 2025 propensity-matched UK Biobank analysis confirmed significant risk reductions for both coronary heart disease (HR 0.92) and heart failure (HR 0.88) among regular glucosamine users.

Cancer

Across studies, glucosamine use is consistently associated with modestly lower cancer mortality. The UK Biobank study showed a 6% reduction in cancer mortality; the VITAL cohort found a 13% reduction. The 2025 propensity-matched study identified particularly strong associations with reduced risk of esophageal cancer (27% reduction) and colorectal cancer (14% reduction).

The anti-cancer mechanisms are plausible: NF-κB signaling is implicated in inflammation-related cancers, AMPK activation opposes the Warburg effect (the metabolic shift toward glycolysis that many cancers rely on), and autophagy helps clear pre-cancerous cellular damage.

Dementia and Cognitive Decline

The dementia data is particularly intriguing, though less settled than the cardiovascular evidence. A 2023 study in BMC Medicine (Zheng et al.) found that regular glucosamine use was associated with a 15% lower risk of all-cause dementia, 17% lower risk of Alzheimer’s disease, and 26% lower risk of vascular dementia. The MR component of this study also supported a causal relationship.

A separate UK Biobank analysis (Zhou et al., 2023) specifically found that glucosamine was significantly associated with reduced risk of vascular dementia (HR 0.83), though not with Alzheimer’s or frontotemporal dementia.

However, a 2024 study (published in The Journals of Gerontology) found no significant associations between glucosamine and dementia or Parkinson’s disease, so the cognitive protection evidence remains mixed. The vascular dementia signal is the most consistent, which makes mechanistic sense given glucosamine’s cardiovascular benefits.

Respiratory Disease

Respiratory disease mortality shows some of the largest effect sizes: a 27% reduction in the UK Biobank study and even larger reductions in the VITAL cohort. The 2025 analysis also found a significant 14% reduction in COPD incidence. The mechanism likely involves NF-κB-mediated suppression of chronic airway inflammation.

Sarcopenia and Physical Function

A 2024 Mendelian randomization study (Kang et al., Frontiers in Endocrinology) found that genetically predicted glucosamine use was causally associated with enhanced cognitive function and delayed sarcopenia — the age-related loss of muscle mass and strength. The effect appeared to be partially mediated through changes in basal metabolic rate and C-reactive protein levels.

Important Caveats and Open Questions

The Healthy User Bias

The single biggest limitation of the mortality evidence is that it comes predominantly from observational studies. People who take glucosamine may systematically differ from non-users in ways that are difficult to fully control for — they may be more health-conscious, have better healthcare access, or engage in other protective behaviors.

The Mendelian randomization studies help address this concern, and the consistency of findings across different populations (US, UK, Australia) with different confounding structures is reassuring. But we don’t yet have the gold standard: a large, long-term randomized controlled trial specifically testing glucosamine’s effects on mortality and healthspan.

Your donations make this website possible. To donate using Buymeacoffee, please visit buymeacoffee.com/nilsosmar

Dose, Form, and Duration

Most of the epidemiological studies classified people simply as “users” or “non-users” without detailed information on dosage or formulation. Standard doses in clinical practice are typically 1,500 mg/day, usually as glucosamine sulfate or glucosamine hydrochloride. Some evidence suggests glucosamine hydrochloride may have advantages, though the data on longevity specifically doesn’t distinguish between forms.

The benefits appear to require consistent, long-term use — the NHANES study specifically looked at daily use for a year or more.

The Atrial Fibrillation Signal

A February 2025 mouse study (published in Metabolism) found that long-term high-dose glucosamine supplementation increased susceptibility to atrial fibrillation by suppressing AMPK signaling in atrial tissue — even while improving systemic insulin sensitivity. This is a counterintuitive finding that deserves attention. The dose used in the high-dose group was substantially above typical human supplementation levels, but it suggests that AMPK effects may be tissue-specific and that more isn’t necessarily better.

People with existing atrial fibrillation or elevated risk factors for it may want to discuss glucosamine use with their cardiologist.

Correlation vs. Causation

Despite the supporting evidence from MR studies, animal models, and mechanistic research, I should be clear that the case for glucosamine as a longevity intervention remains probabilistic rather than proven. (This of course is also true of other supposed longevity-boosting drugs and supplements.) The evidence is stronger than for most supplements — considerably stronger — but it has not been established by randomized controlled trials in humans with mortality endpoints.

That said, it’s important to put this limitation in context. Mortality endpoint RCTs would require following large populations for decades — an enormous investment of time and money — and essentially no dietary supplement has ever been validated by this standard. Even in the pharmaceutical world, only a handful of drugs have cleared this bar, and those are backed by the resources of major pharmaceutical companies with strong financial incentives to fund such trials.

Metformin, widely regarded as one of the more promising longevity interventions available, is in a similar evidentiary position to glucosamine: strong observational data, compelling mechanisms, and animal lifespan extension — but the definitive human trial (TAME) is still underway.

The absence of mortality RCTs for glucosamine reflects the practical realities of longevity research, not a weakness specific to glucosamine’s evidence base. By the standards that actually apply to dietary supplements — large prospective cohorts, Mendelian randomization, mechanistic research, and animal lifespan studies — glucosamine’s case is unusually robust.

Practical Considerations

Dosage: The standard dose used in osteoarthritis studies is 1,500 mg/day, typically taken as a single dose or split into three 500 mg doses. This is likely a reasonable target for potential longevity benefits as well.

Form: Glucosamine sulfate and glucosamine hydrochloride are the two most common forms. Some clinical evidence favors glucosamine hydrochloride. Glucosamine derived from shellfish is the most common source, though fungal-derived versions are available for those with shellfish allergies.

With or without chondroitin? The UK Biobank analyses suggest that the mortality benefits persist when chondroitin users are excluded, indicating that glucosamine alone is sufficient. However, chondroitin has its own anti-inflammatory properties and the combination may offer additional joint-specific benefits.

Cost: Glucosamine is one of the most affordable longevity-relevant supplements available. A month’s supply at 1,500 mg/day typically costs $8–15, depending on the brand and form.

Safety: Decades of use and multiple clinical trials have established glucosamine as very safe for most people. Occasional side effects include mild gastrointestinal symptoms (nausea, heartburn, diarrhea). People with shellfish allergies should use non-shellfish-derived forms. Those taking blood thinners (warfarin) should consult their doctor, as there have been case reports of interactions.

Timing considerations: For those practicing AMPK/mTOR cycling protocols, glucosamine’s identity as a glycolytic inhibitor and AMPK activator makes it a natural fit for the fasting or AMPK-activation phase of the day — taken in the morning or during the fasting window, before switching to protein-rich meals that activate mTOR.

Your donations make this website possible. To donate using Buymeacoffee, please visit buymeacoffee.com/nilsosmar

Interactions with other supplements

While the studies discussed above did control for chondroitin use, the effects of taking glucosamine alongside other popular longevity-oriented supplements — such as berberine, metformin, rapamycin, fucoidan, NMN, or other AMPK activators — have not been studied.

It’s an open question whether combining glucosamine with other compounds that target the same pathways (AMPK activation, mTOR inhibition, autophagy induction) might enhance its benefits through synergy, or whether overlapping mechanisms might produce diminishing returns — or even interfere with one another. This is a significant gap in the research, and one worth keeping in mind if you’re incorporating glucosamine into a broader supplement protocol.

The mortality data we have reflects glucosamine use in the general population, not in people running sophisticated longevity stacks. The truth is that we simply don’t know whether it is good or bad to combine it with other supplements or medications.

What I’m Doing

I have been on and off about taking glucosamine. I recently resumed taking it after a break of several months. My feeling during the period when I was avoiding it was that I was already taking several other supplements that activated AMPK, and also doing the time restricted eating several days a week, which has the same benefit.

My current focus is on moving in the direction of taking fewer expensive supplements that are not well proven, and in the direction of taking ones that are both more affordable and are better vetted. Ones like glucosamine, magnesium, vitamin D and some others would make the list.

See related article: the Best-Vetted Anti-Aging Supplements

The Bottom Line

Glucosamine occupies a rare position in the supplement landscape: it’s cheap, safe, widely available, backed by consistent large-scale epidemiological data showing 15–39% reductions in all-cause mortality, supported by Mendelian randomization evidence suggesting causality, and underpinned by a well-characterized mechanism of action involving AMPK activation, autophagy induction, and chronic inflammation suppression.

No supplement is a magic bullet, and the evidence, while strong by supplement standards, still falls short of the randomized controlled trial gold standard. But given the risk-benefit calculus — minimal downside, substantial potential upside, and a price point that makes it accessible to almost everyone — my perosnal assessment is that glucosamine deserves serious consideration as part of a longevity-oriented supplement strategy.

Millions of people nowadays are spending hundreds of dollars a month on supplements which there is far less reason to believe might have longevity benefits.

Key Studies Referenced

1. Li Z-H, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. Ann Rheum Dis. 2020;79(6):829-836.
   
2. King DE, Xiang J. Glucosamine/chondroitin and mortality in a US NHANES cohort. J Am Board Fam Med. 2020;33(6):842-847. doi:10.3122/jabfm.2020.06.200110.
   
3. Pocobelli G, et al. Use of glucosamine and chondroitin in relation to mortality. Am J Epidemiol. 2010;171(9):1089-1097.
   
4. Weimer S, et al. D-Glucosamine supplementation extends life span of nematodes and of ageing mice. Nat Commun. 2014;5:3563. doi:10.1038/ncomms4563.
   
5. Ma H, et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ. 2019;365:l1628.
   
6. Zheng J, et al. Association of regular glucosamine use with incident dementia: evidence from a longitudinal cohort and Mendelian randomization study. BMC Med. 2023;21(1):114. doi:10.1186/s12916-023-02816-8.
   
7. Zhou Y, et al. Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia. Alzheimers Res Ther. 2023;15:156.
   
8. Qin X, et al. Long-term glucosamine supplementation aggravates atrial fibrillation susceptibility by impairing AMPK signaling. Life Sci. 2025;362:123380. doi:10.1016/j.lfs.2025.123380

More from Nils Osmar

• Anti-Aging Youtube channel Pathways to Longevity
• Anti-Aging Facebook group: Anti-Aging and Life Extension
• Rekindle School classes in Seattle: Rekindl.e School
• My personal website: My articles, art and more: Nilsosmar.com
• Exploring possible consciousness in Claude.AI and other LLMs: AI Consciousness
• Donations make this website possible. To donate using Buymeacoffee, please click here